Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $38.0833.

A number of brokerages recently commented on JANX. JonesTrading decreased their price target on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Monday, July 20th. Evercore set a $22.00 target price on Janux Therapeutics in a research report on Monday, May 11th. Guggenheim lowered their target price on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Piper Sandler cut their price target on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, May 8th.

Insider Activity

In other Janux Therapeutics news, VP Maria Dobek sold 2,038 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $14.17, for a total value of $28,878.46. Following the transaction, the vice president directly owned 32,270 shares in the company, valued at $457,265.90. The trade was a 5.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the transaction, the insider directly owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 7.90% of the company’s stock.

Institutional Trading of Janux Therapeutics

Large investors have recently bought and sold shares of the company. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Janux Therapeutics in the fourth quarter valued at $34,000. Versant Capital Management Inc increased its holdings in Janux Therapeutics by 42.8% in the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after acquiring an additional 784 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Janux Therapeutics in the 4th quarter valued at about $51,000. Osaic Holdings Inc. lifted its holdings in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $15.33 on Friday. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34. The stock has a market cap of $934.82 million, a PE ratio of -8.33 and a beta of 2.52. The firm’s 50-day simple moving average is $14.81 and its 200 day simple moving average is $14.33.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. As a group, analysts predict that Janux Therapeutics will post -1.7 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.